ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2013
Drug expenditure of high-cost patients and their characteristics in Finland.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 33 citations in OpenAlex.
- Drawing up the public national Rational Pharmacotherapy Action Plan as part of social and health services reform in Finland: a bottom-up approach involving stakeholders.BMC health services research · 2024Article
- Characteristics of High-Cost Beneficiaries of Prescription Drugs in Kazakhstan: A Cross-Sectional Study of Outpatient Data from 2022.ClinicoEconomics and outcomes research : CEOR · 2024Article
- High-Cost Users of Prescription Drugs: National Health Insurance Data from South Korea.Journal of general internal medicine · 2022Observational
- Integrating medication risk management interventions into regular automated dose dispensing service of older home care clients - a systems approach.BMC geriatrics · 2021Article
- Factors associated with prescribing costs: analysis of a nationwide administrative database.Cost effectiveness and resource allocation : C/E · 2018Article
- Article
- High-Cost Users of Prescription Drugs: A Population-Based Analysis from British Columbia, Canada.Health services research · 2017Article
- Characteristics and drug utilization patterns for heavy users of prescription drugs among the elderly: a Danish register-based drug utilization study.European journal of clinical pharmacology · 2015Article
- Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer's disease.Annals of medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle information exists on how constantly growing pharmaceutical expenditures are distributed in large representative samples of national populations in Western countries.
objectiveThis study analyzes the distribution of pharmaceutical expenditures in ambulatory care and explores the basic characteristics of the high-cost drug users.
methodReimbursed prescription drug purchases in 2009 were derived from the National Prescription Register for a 50% sample of the adult Finnish population. The high-cost users who were among the top 5% in terms of drug expenditures were identified based on annual drug costs.
resultsThe distribution of pharmaceutical costs is strongly skewed in Finland; only 5% of the population accounts for about half of the costs. These high-cost drug users were older than the low-cost drug users, with more than one-fourth of them being over 75 years old. The high-cost drug users used, on average, more drugs than the low-cost drug users, but approximately 15% of them used only 1-5 drugs. Almost 50% of the high-cost drug users used more than 10 drugs per year. They had chronic diseases more often than the low-cost drug users, especially uremia requiring dialysis, post-transplant conditions, severe anemia associated with chronic renal failure and multiple sclerosis were common among the high-cost users.
conclusionThe skewness of the cost distribution indicates a need for more patient-specific cost-containment methods, and the high number of drugs in the high-cost group calls for exploring the possibilities of disease management and patient monitoring techniques in cost containment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.